September 12, 2019 — CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular assist device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO), Sept. 8-12 in Hannover, Germany.
Trevor Snyder, Ph.D., senior director, translational and clinical research at CorWave, delivered an oral presentation, “CorWave LVAD: A physiologic, pulsatile-flow wave membrane pump.”
CorWave previously reported on the successful completion of 30-day follow-up of an earlier in vivo study. The final results of the 60-day experience, presented at the ESAO conference, confirm the CorWave pump’s ability to provide chronic circulatory support with outstanding hemocompatibility.
The CorWave technology features a physiologic design enabled by its unique undulating membrane. Among other advantages, the membrane is able to generate a natural pulse, replicating the blood flow and pressure characteristics of the patient’s native heart. CorWave’s membrane pump technology is being developed to reduce complications associated with current devices and improve the care of patients with heart failure.
For more information: www.corwave.com
June 19, 2024 
